Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?

Published:2022-10-18 Issue:16 Volume:146 Page:1207-1209
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Gue Ying X.¹,Gorog Diana A.²³^ORCID,Lip Gregory Y.H.¹⁴^ORCID

Affiliation:

1. Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom (Y.X.G., G.Y.H.L.).

2. School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, United Kingdom (D.A.G.).

3. Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom (D.A.G.).

4. Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference13 articles.

1. Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management

2. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

3. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients

4. State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism

5. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP